Curasight: Theranostics platform with broad potential - Redeye

Redeye initiates coverage of Curasight, a Danish biotech company offering a theranostics platform (therapy + diagnostics) in the field of PET imaging and radioligand (local radiation) therapy based on the novel use of the versatile uPAR cancer biomarker. We see broad potential in the company’s technology if Curasight can demonstrate additional encouraging data and deliver on its strategy.

Länk till analysen i sin helhet: https://www.redeye.se/research/949804/curasight-theranostics-platform-with-broad-potential?utm_source=finwire&utm_medium=RSS